search
Back to results

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. (MOVE)

Primary Purpose

Fibrodysplasia Ossificans Progressiva

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Palovarotene
Sponsored by
Clementia Pharmaceuticals Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fibrodysplasia Ossificans Progressiva focused on measuring Interventional study, Clinical trial phase 3, Efficacy and safety, Heterotopic ossification, Flare-up, Palovarotene, Retinoic acid receptor agonist, Retinoic acid receptor gamma agonist, Clementia, Myositis Ossificans Progressiva, Munchmeyer's Disease, FOP, FOP variants

Eligibility Criteria

4 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Written, signed, and dated informed subject/parent consent; and for subjects who are minors, age-appropriate assent (performed according to local regulations).
  • Males or females at least 4 years of age.
  • Previous participation in Clementia's natural history study (NCT02322255); clinically diagnosed with FOP, with the R206H ACVR1 mutation or other FOP variants reported to be associated with progressive HO (who have not participated in any Clementia-sponsored study); participants in Clementia's Phase 2 studies (NCT02279095 and NCT02979769) who cannot currently receive the chronic/flare-up regimen due to country of residence or those traveling long distances to participate in the Phase 2 studies.
  • No flare-up symptoms within the past 4 weeks, including at the time of enrollment.
  • Abstinent or using two highly effective forms of birth control.
  • Accessible for treatment and follow-up; able to undergo all study procedures including low-dose WBCT (excluding head) without sedation.

Key Exclusion Criteria:

  • Weight <10 kg.
  • Concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity; or kinase inhibitors such as imatinib.
  • Amylase or lipase >2x above the upper limit of normal (ULN) or with a history of chronic pancreatitis.
  • Elevated aspartate aminotransferase or alanine aminotransferase >2.5x ULN.
  • Fasting triglycerides >400 mg/dL with or without therapy.
  • Female subjects who are breastfeeding.
  • Subjects with uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease.
  • Simultaneous participation in another clinical research study (other than palovarotene studies) within 4 weeks prior to Screening; or within five half-lives of the investigational agent, whichever is longer.
  • Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.

Sites / Locations

  • University of California San Francisco, Division of Endocrinology and Metabolism
  • Mayo Clinic - PIN
  • Children's Hospital of Philadelphia
  • University of Pennsylvania, Internal Medicine
  • Hospital Italiano de Buenos Aires, Tte General Juan Domingo Peron 4190
  • Royal North Shore Hospital
  • Queensland University of Technology
  • Hospital Israelita Albert Einstein
  • Hospital for Sick Children, 555 University Avenue
  • Toronto General Hospital
  • Groupe Hospitalier Necker Enfants Malades
  • Istituto Giannina Gaslini
  • The University of Tokyo Hospital
  • Hospital Universitari i Politècnic La Fe, Unidad de Reumatología Pediatrica
  • Norrlands Universitetssjukhus
  • Royal National Orthopaedic Hospital, Brockely Hill

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Palovarotene Chronic/Flare-Up Regimen

Arm Description

Participants received 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing was adjusted for weight in skeletally immature subjects.)

Outcomes

Primary Outcome Measures

Annualized New Heterotopic Ossification (HO)
The annualized new HO was assessed by low-dose, whole body computed tomography (WBCT), excluding head. The weighted linear mixed effect method without square-root transformation and negatives included was used for annualized new HO analysis.

Secondary Outcome Measures

Percentage of Participants With Any New HO
The new HO was assessed by WBCT scan. The percentage of participants with any new HO (volume > 0 mm^3) were analyzed using the Bayesian distribution.
Number of Participants With Body Regions With New HO
The number of participants with any new HO (new HO > 0 mm^3) by number of body regions are reported. The presence of HO across various body regions was analyzed using WBCT scan.
Percentage of Participants With Flare-Ups
Flare-up as an event with one or more flare-up symptoms, and regardless of flare-up symptom onset. Flare-up was evaluated remotely, or by telephone or video-conferencing, unless the Investigator deemed that a site visit was necessary.
Ratio of Flare-Up Per Participant-Month of Exposure Through Month 24
Flare-up as an event with one or more flare-up symptoms, and regardless of flare-up symptom onset. Flare-up was evaluated remotely, or by telephone or video-conferencing, unless the Investigator deemed that a site visit was necessary. The flare-up rate per participant-month exposure was analyzed using a negative binomial regression.

Full Information

First Posted
October 9, 2017
Last Updated
March 10, 2023
Sponsor
Clementia Pharmaceuticals Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03312634
Brief Title
An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Acronym
MOVE
Official Title
A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
November 30, 2017 (Actual)
Primary Completion Date
January 24, 2020 (Actual)
Study Completion Date
September 7, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Clementia Pharmaceuticals Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability.
Detailed Description
One of the primary objectives was to evaluate the efficacy of palovarotene in decreasing new HO in participants with FOP as assessed by low-dose, whole body computed tomography (WBCT), excluding head, compared to untreated participants from Clementia's FOP natural history study (Study PVO-1A-001, NHS). The other primary objective was to evaluate the safety of palovarotene in participants with FOP. This study was conducted in three parts. Part A was the main part of the study and Part B, the 2-year (24-month) extension. Eligible participants received a chronic/flare-up dosing regimen of palovarotene for 4 years (48 months) as follows: Chronic treatment: orally administered 5 mg palovarotene once daily for 2 years (24 months). Flare-up treatment: orally administered 20 mg palovarotene once daily for 4 weeks (28 days) followed by orally administered 10 mg palovarotene once daily for 8 weeks (56 days). Flare-up treatment may be extended until the Investigator determines that the flare-up has resolved. Note that all dosing was weight-adjusted in skeletally immature participants (those under the age of 18 years with less than 90% skeletal maturity on hand/wrist x-rays performed at Screening). Part C was an up-to-2-year post last dose of study treatment follow-up for skeletally immature participants. No new participants were enrolled into Part C. Participants who were enrolled in Parts A or B who discontinued the study and were skeletally immature were invited back to participate in the off-treatment Part C safety follow-up.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibrodysplasia Ossificans Progressiva
Keywords
Interventional study, Clinical trial phase 3, Efficacy and safety, Heterotopic ossification, Flare-up, Palovarotene, Retinoic acid receptor agonist, Retinoic acid receptor gamma agonist, Clementia, Myositis Ossificans Progressiva, Munchmeyer's Disease, FOP, FOP variants

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Model Description
A multicenter, open-label study. NHS data (study PVO-1A-001) will be used as an external control in the analysis.
Masking
None (Open Label)
Allocation
N/A
Enrollment
107 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Palovarotene Chronic/Flare-Up Regimen
Arm Type
Experimental
Arm Description
Participants received 5 mg palovarotene once daily for up to 24 months; and 20 mg palovarotene once daily for 28 days, followed by 10 mg for 56 days for flareups. (Dosing was adjusted for weight in skeletally immature subjects.)
Intervention Type
Drug
Intervention Name(s)
Palovarotene
Intervention Description
Palovarotene was taken orally once daily at approximately the same time each day following a meal.
Primary Outcome Measure Information:
Title
Annualized New Heterotopic Ossification (HO)
Description
The annualized new HO was assessed by low-dose, whole body computed tomography (WBCT), excluding head. The weighted linear mixed effect method without square-root transformation and negatives included was used for annualized new HO analysis.
Time Frame
Baseline (within one month of screening/Day 1) and up to 24 months
Secondary Outcome Measure Information:
Title
Percentage of Participants With Any New HO
Description
The new HO was assessed by WBCT scan. The percentage of participants with any new HO (volume > 0 mm^3) were analyzed using the Bayesian distribution.
Time Frame
Month 12
Title
Number of Participants With Body Regions With New HO
Description
The number of participants with any new HO (new HO > 0 mm^3) by number of body regions are reported. The presence of HO across various body regions was analyzed using WBCT scan.
Time Frame
Month 12
Title
Percentage of Participants With Flare-Ups
Description
Flare-up as an event with one or more flare-up symptoms, and regardless of flare-up symptom onset. Flare-up was evaluated remotely, or by telephone or video-conferencing, unless the Investigator deemed that a site visit was necessary.
Time Frame
Month 12
Title
Ratio of Flare-Up Per Participant-Month of Exposure Through Month 24
Description
Flare-up as an event with one or more flare-up symptoms, and regardless of flare-up symptom onset. Flare-up was evaluated remotely, or by telephone or video-conferencing, unless the Investigator deemed that a site visit was necessary. The flare-up rate per participant-month exposure was analyzed using a negative binomial regression.
Time Frame
From Baseline (Day 1) up to Month 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Written, signed, and dated informed subject/parent consent; and for subjects who are minors, age-appropriate assent (performed according to local regulations). Males or females at least 4 years of age. Previous participation in Clementia's natural history study (NCT02322255); clinically diagnosed with FOP, with the R206H ACVR1 mutation or other FOP variants reported to be associated with progressive HO (who have not participated in any Clementia-sponsored study); participants in Clementia's Phase 2 studies (NCT02279095 and NCT02979769) who cannot currently receive the chronic/flare-up regimen due to country of residence or those traveling long distances to participate in the Phase 2 studies. No flare-up symptoms within the past 4 weeks, including at the time of enrollment. Abstinent or using two highly effective forms of birth control. Accessible for treatment and follow-up; able to undergo all study procedures including low-dose WBCT (excluding head) without sedation. Key Exclusion Criteria: Weight <10 kg. Concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity; or kinase inhibitors such as imatinib. Amylase or lipase >2x above the upper limit of normal (ULN) or with a history of chronic pancreatitis. Elevated aspartate aminotransferase or alanine aminotransferase >2.5x ULN. Fasting triglycerides >400 mg/dL with or without therapy. Female subjects who are breastfeeding. Subjects with uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease. Simultaneous participation in another clinical research study (other than palovarotene studies) within 4 weeks prior to Screening; or within five half-lives of the investigational agent, whichever is longer. Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ipsen Medical Director
Organizational Affiliation
Ipsen
Official's Role
Study Director
Facility Information:
Facility Name
University of California San Francisco, Division of Endocrinology and Metabolism
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
Mayo Clinic - PIN
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Children's Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
University of Pennsylvania, Internal Medicine
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Hospital Italiano de Buenos Aires, Tte General Juan Domingo Peron 4190
City
Buenos Aires
ZIP/Postal Code
C1199ACH
Country
Argentina
Facility Name
Royal North Shore Hospital
City
Saint Leonards
State/Province
New South Wales
ZIP/Postal Code
2065
Country
Australia
Facility Name
Queensland University of Technology
City
Woolloongabba
State/Province
Queensland
ZIP/Postal Code
4102
Country
Australia
Facility Name
Hospital Israelita Albert Einstein
City
Sao Paulo
State/Province
SP
ZIP/Postal Code
05652-900
Country
Brazil
Facility Name
Hospital for Sick Children, 555 University Avenue
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X8
Country
Canada
Facility Name
Toronto General Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2C4
Country
Canada
Facility Name
Groupe Hospitalier Necker Enfants Malades
City
Paris
ZIP/Postal Code
75015
Country
France
Facility Name
Istituto Giannina Gaslini
City
Genoa
State/Province
Liguria
ZIP/Postal Code
16147
Country
Italy
Facility Name
The University of Tokyo Hospital
City
Tokyo
State/Province
Bunkyo-ku
ZIP/Postal Code
113-8655
Country
Japan
Facility Name
Hospital Universitari i Politècnic La Fe, Unidad de Reumatología Pediatrica
City
Valencia
State/Province
Avinguda De Fernando Abril Martorell, Nº 106
ZIP/Postal Code
46026
Country
Spain
Facility Name
Norrlands Universitetssjukhus
City
Umeå
ZIP/Postal Code
SE-90185
Country
Sweden
Facility Name
Royal National Orthopaedic Hospital, Brockely Hill
City
Stanmore
ZIP/Postal Code
HA7 4LP
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
21460849
Citation
Shimono K, Tung WE, Macolino C, Chi AH, Didizian JH, Mundy C, Chandraratna RA, Mishina Y, Enomoto-Iwamoto M, Pacifici M, Iwamoto M. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011 Apr;17(4):454-60. doi: 10.1038/nm.2334. Epub 2011 Apr 3. Erratum In: Nat Med. 2012 Oct;18(10):1592.
Results Reference
background
Links:
URL
http://ifopa.org
Description
Website for the International FOP Association

Learn more about this trial

An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.

We'll reach out to this number within 24 hrs